Torrent Pharmaceuticals Limited
TORNTPHARM
株式のランク
#1201
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
株価
$50.31
最終同期: 2026-10-19
時価総額
$19.14B
変化（1日）
-0.14%
変化（1年）
23.83%
国
IN
取引 Torrent Pharmaceuticals Limited (TORNTPHARM)
カテゴリー
Healthcare
Torrent Pharmaceuticals Limited（TORNTPHARM）の利益
Jun 2026 時点の利益 TTM: $316.40M
Torrent Pharmaceuticals Limited の最新の財務報告によると、同社の現在の利益は $316.40M です。2024 年には $282.08M の利益を上げ、これは 2023 年の利益 $224.77M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Torrent Pharmaceuticals Limited の利益の推移（2005 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $316.40M | 1.24% |
| 2025 | $312.51M | 10.79% |
| 2024 | $282.08M | 25.50% |
| 2023 | $224.77M | 39.18% |
| 2022 | $161.50M | -22.54% |
| 2021 | $208.49M | 32.37% |
| 2020 | $157.51M | 94.73% |
| 2019 | $80.88M | -43.43% |
| 2018 | $142.99M | -14.78% |
| 2017 | $167.79M | -52.57% |
| 2016 | $353.73M | 134.86% |
| 2015 | $150.61M | -3.94% |
| 2014 | $156.79M | 46.48% |
| 2013 | $107.04M | 51.35% |
| 2012 | $70.72M | -8.03% |
| 2011 | $76.89M | -0.54% |
| 2010 | $77.31M | 104.22% |
| 2009 | $37.86M | 1.60% |
| 2008 | $37.26M | 48.13% |
| 2007 | $25.15M | 44.18% |
| 2006 | $17.45M | 33.96% |
| 2005 | $13.02M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 457.70% |
IN
|
